Australia's most trusted
source of pharma news
Tuesday, 16 June 2026
Posted 16 June 2026 PM
A shortage of Viatris's PBS-listed pancreatic enzyme replacement therapy Creon will continue until into next year.
"Viatris has notified us that supply constraints affecting Creon 25,000-unit and Creon 35,000-unit capsules will continue until 31 January 2027 due to an unexpected global increase in demand," the TGA announced last week.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.